These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17848835)

  • 21. Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period.
    Karapanou O; Tzanela M; Christoforaki M; Papastathopoulou L; Moutsatsou P; Botoula E; Tsagarakis S
    Hormones (Athens); 2016 Jul; 15(3):368-376. PubMed ID: 27394702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
    Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
    Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era.
    Butz LB; Sullivan SE; Chandler WF; Barkan AL
    Pituitary; 2016 Dec; 19(6):547-551. PubMed ID: 27497970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-Dose Gamma Knife Radiosurgery for Acromegaly.
    Pai FY; Chen CJ; Wang WH; Yang HC; Lin CJ; Wu HM; Lin YC; Chen HS; Yen YS; Chung WY; Guo WY; Pan DH; Shiau CY; Lee CC
    Neurosurgery; 2019 Jul; 85(1):E20-E30. PubMed ID: 30169716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly.
    Sarkar S; Chacko AG; Chacko G
    Acta Neurochir (Wien); 2014 Dec; 156(12):2221-30; discussion 2230. PubMed ID: 25238988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
    Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
    J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advances in the treatment of acromegaly].
    Krysiak R; Okopień B; Marek B
    Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3D Volumetric Measurements of GH Secreting Adenomas Correlate with Baseline Pituitary Function, Initial Surgery Success Rate, and Disease Control.
    Tirosh A; Papadakis GZ; Chittiboina P; Lyssikatos C; Belyavskaya E; Keil M; Lodish MB; Stratakis CA
    Horm Metab Res; 2017 Jun; 49(6):440-445. PubMed ID: 28472827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pituitary tumours: acromegaly.
    Chanson P; Salenave S; Kamenicky P; Cazabat L; Young J
    Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):555-74. PubMed ID: 19945023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
    Maiza JC; Vezzosi D; Matta M; Donadille F; Loubes-Lacroix F; Cournot M; Bennet A; Caron P
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of specific growth patterns and frequency of the empty sella phenomenon in growth hormone-secreting pituitary adenomas.
    Bier G; Hempel JM; Grimm F; Ernemann U; Bender B; Honegger J
    Eur J Radiol; 2018 Jul; 104():79-86. PubMed ID: 29857870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
    Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
    Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
    Fusco A; Zatelli MC; Bianchi A; Cimino V; Tilaro L; Veltri F; Angelini F; Lauriola L; Vellone V; Doglietto F; Ambrosio MR; Maira G; Giustina A; degli Uberti EC; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2746-50. PubMed ID: 18460561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'.
    Nomikos P; Buchfelder M; Fahlbusch R
    Eur J Endocrinol; 2005 Mar; 152(3):379-87. PubMed ID: 15757854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
    Kreutzer J; Vance ML; Lopes MB; Laws ER
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4072-7. PubMed ID: 11549628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of immunostaining for growth hormone in a subset of patients with acromegaly.
    Schroeder JL; Spiotta AM; Fleseriu M; Prayson RA; Hamrahian AH; Weil RJ
    Pituitary; 2014 Apr; 17(2):103-8. PubMed ID: 23475513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
    Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
    Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
    Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation.
    Xu T; Ye F; Wang B; Tian C; Wang S; Shu K; Guo D; Lei T
    Neuro Endocrinol Lett; 2010; 31(1):147-54. PubMed ID: 20150876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octreotide lar affects the volume of pituitary adenoma in acromegalic patients.
    Bałdys-Waligórska A; Krzentowska-Korek A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
    Exp Clin Endocrinol Diabetes; 2011 May; 119(5):295-9. PubMed ID: 21264808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.